Mathews, Mona
Wißfeld, Jannis
Flitsch, Lea Jessica
Shahraz, Anahita
Semkova, Vesselina
Breitkreuz, Yannik
Neumann, Harald
Brüstle, Oliver
Funding for this research was provided by:
Innovative Medicines Initiative (115976)
Universitätsklinikum Bonn
Article History
Accepted: 19 July 2022
First Online: 15 August 2022
Declarations
:
: All human iPSC lines used in this project were either previously generated with approval of the Ethics Committee of the Medical Faculty of the University of Bonn (approval number 275/08; relevant for iLB-C133bm-S4, iLB-C14m-S11 and iLB-31f-r1) or kindly provided by Janssen Pharmaceutica N.V (relevant for Bioni010-C). The Bioni010-C line is deposited at the European Bank for Induced pluripotent Stem Cells (EBiSC; ExternalRef removed).
: Not applicable.
: Not applicable.
: OB and HN are inventors on a patent relating to the generation of microglial precursors from pluripotent stem cells (WO2010125110A1). MM and OB are inventors on a patent application relating to up-scaled production of microglia-like cells and macrophages using mesh macrocarriers (WO2021180781). Both patents are assigned to the LIFE & BRAIN GmbH and the University of Bonn.MM, YB and OB are employed by LIFE & BRAIN GmbH. OB is a co-founder and shareholder of LIFE & BRAIN GmbH.JW, LJF, AS and VS declare no conflicts of interest.